DDInter1476 DDInter1376
Pirbuterol is a beta-2 adrenergic bronchodilator. In vitro studies and in vivo pharmacologic studies have demonstrated that pirbuterol has a preferential effect on beta-2 Adrenergic receptors compared with isoproterenol. While it is recognized that beta-2 adrenergic receptors are the predominant receptors in bronchial smooth muscle, data indicate that there is a population of beta-2 receptors in the human heart, existing in a concentration between 10-50%. The precise function of these receptors has not been established. The pharmacologic effects of beta adrenergic agonist drugs, including pirbuterol, are at least in proof attributable to stimulation through beta adrenergic receptors of intracellular adenyl cyclase, the enzyme which catalyzes the conversion of adenosine triphosphate (AlP) to cyclic-3†,5†-adenosine monophosphate (c-
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Pirbuterol {u} (Compound) resembles {v} (Compound) Bupranolol
Pirbuterol {u} (Compound) resembles {v} (Compound) Terbutaline
Pirbuterol {u} (Compound) treats {v} (Disease) asthma
Pirbuterol {u} (Compound) binds {v} (Gene) ADRB1
Pirbuterol {u} (Compound) is included by {v} (Pharmacologic Class) Adrenergic beta2-Agonists
Pirbuterol {u} (Compound) causes {v} (Side Effect) Dry mouth
Pirbuterol (Compound) resembles Bupranolol (Compound)
Pirbuterol (Compound) resembles Terbutaline (Compound)
Pirbuterol (Compound) treats asthma (Disease)
Pirbuterol (Compound) binds ADRB1 (Gene)
Pirbuterol (Compound) is included by Adrenergic beta2-Agonists (Pharmacologic Class)
Pirbuterol (Compound) causes Dry mouth (Side Effect)